Ignite Creation Date:
2024-05-06 @ 8:12 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06298656
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-03-07
First Post:
2024-03-01
Brief Title:
Acute hemodynamiC Response To Carvedilol Predicts Survival in ACLF Patients
Sponsor:
Institute of Liver and Biliary Sciences India
Organization:
Institute of Liver and Biliary Sciences India
Study Overview
Official Title:
Acute hemodynamiC Response To Carvedilol Predicts Survival in ACLF Patients - ACT - C ACLF Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Clinically significant portal hypertension CSPH is defined as HVPG 10 mmHg Patients with CSPH are at risk of developing esophageal varices and clinical decompensation variceal bleeding ascites jaundice encephalopathy which mark the transition from compensated stage to a stage of the disease decompensated associated with higher mortality 1 HVPG is calculated by subtracting the free hepatic venous pressure FHVP a measure of systemic pressure from the wedged hepatic venous pressure WHVP a measure of hepatic sinusoidal pressure HVPG is surrogate marker in many clinical applications such as gold standard test to evaluate presence and severity of portal hypertension PHT diagnosis risk stratification monitoring of the patients on beta blockers 2 Non selective beta-blockers like propranolol and carvedilol are indicated in adults for primary and secondary prophylaxis of variceal hemorrhage Acute hemodynamic response to intravenous propranolol with HVPG values coming down to 12 mm Hg or reduction to 20 from baseline have been shown to be associated with reduced long term risk of variceal bleed Hence we are planning the current work to study the Acute hemodynamiC response To Carvedilol predicts survival in ACLF patients - ACT - C ACLF study
Detailed Description:
To assess whether Acute hemodynamic response to oral Carvedilol can predict short term outcome in ACLF patients
To determine the best cut off to define acute hemodynamic response in ACLF patients
Primary outcome - Predictive value of acute HVPG change by carvedilol for 28 day transplant free survival in patients of ACLF
Secondary outcome -
1 Complications PHT related bleed AKI infections HE Hypotension Cardiac side effect within 90 days 2 Transplant-free survival rate at 90 days 3 Correlation with evolution of AARC score by 2 week
b Methodology
Study population Patients of age 18 to 70 years with ACLF fulfilling the conditions as per inclusion and exclusion criteria
Baseline parameters that will be recorded
1 Baseline characteristics
2 History and etiology of liver disease
3 Symptomatology Evidence of decompensation jaundice encephalopathy ascites infections variceal bleed etc
4 Clinical and demographic profile
5 Endoscopy
Stopping rule of study
1 Progression to exclusion criteria
2 In case of hypotension9060mmHg or Heart Rate 60 after carvedilol
3 Potential liver transplant within 90 days
To determine the best cut off to define acute hemodynamic response in ACLF patients
Primary outcome - Predictive value of acute HVPG change by carvedilol for 28 day transplant free survival in patients of ACLF
Secondary outcome -
1 Complications PHT related bleed AKI infections HE Hypotension Cardiac side effect within 90 days 2 Transplant-free survival rate at 90 days 3 Correlation with evolution of AARC score by 2 week
b Methodology
Study population Patients of age 18 to 70 years with ACLF fulfilling the conditions as per inclusion and exclusion criteria
Baseline parameters that will be recorded
1 Baseline characteristics
2 History and etiology of liver disease
3 Symptomatology Evidence of decompensation jaundice encephalopathy ascites infections variceal bleed etc
4 Clinical and demographic profile
5 Endoscopy
Stopping rule of study
1 Progression to exclusion criteria
2 In case of hypotension9060mmHg or Heart Rate 60 after carvedilol
3 Potential liver transplant within 90 days
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None